RxDoctor Payments Data

Valsamo Anagnostou

Medical Oncology · Baltimore, MDNPI 1821314030

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Foundation Medicine, Inc. at 33.3% of the total.

$15,597in general payments, 2019–2025

Across 9 payments — averaging $1732.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Foundation Medicine, Inc.$5K
  • AstraZeneca$5K
  • Astrazeneca UK Limited$3K
  • Life Technologies Corporation$2K
  • Roche Sequencing Solutions, Inc.$1K
$2,011,029in research payments, 2019–2025

Across 8 payments — averaging $251,379 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$1.2M
  • Amgen$762K
  • Regeneron$781

What the payments were for

  • Consulting fees$8,04852%
  • Speaking & faculty fees$7,19046%
  • Travel & lodging$971%
  • Food & beverage$2622%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,597 in reported general payments places this provider in the 70th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Other medical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →